| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a4c41c53e82cdf97e3f0eda90224c45 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16662
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16643
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-869
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 |
| filingDate |
1994-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e981ba2357c771a06a93ad983f22dec2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01147b2c5b6b428fad570cbf5dc868ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b29d4b851d356e79f954c8ca52ead9d7 |
| publicationDate |
1994-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2158148-A1 |
| titleOfInvention |
Defective mutant non-retroviral virus (e.g. hsv) as vaccine |
| abstract |
The application provides a pharmaceutical which comprises a mutant non-retroviral virus (particularly HSV-1 and/or HSV-2) whose genome is defective in respect of a gene essential for the production of infectious virus. The virus can infect normal cells and undergo replication and expression of viral antigen genes in those cells but cannot produce normal infectious virus. The pharmaceutical is for prophylactic or therapeutic use in generating an immune response in a subject infected therewith. Where the non-retroviral virus is a herpes simplex virus e.g. HSV-1 or HSV-2, the defect can be in the glycoprotein gH gene. Vaccines and therapeutic pharmaceuticals are provided especially for epithelial, oral, vaginal and nasal administration. Also provided is use of a mutant based on HSV-1 for the preparation of a pharmaceutical for prophylactic ore therapeutic use in generating an immune response in a subject against type-2 HSV infection. |
| priorityDate |
1993-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |